EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Huoxiang Zhengqi Oral Liquid Attenuates LPS‐Induced Acute Lung Injury by Modulating Short‐Chain Fatty Acid Levels and TLR4/NF‐ κ B p65 Pathway

Ruying Tang iD, Jianjun Zhang iD, Rui Zhang iD, Xinyu Li, Ruilin Lv, Haipeng Nan, Jinlian Liu, Zhongpeng Zhao, Wei He, Linyuan Wang iD

BioMed Research International · 2023

DOI: 10.1155/2023/6183551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2023. Verfasst von Ruying Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Acute Lung Injury, NF-kappa B. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huoxiang Zhengqi Oral Liquid (HZOL) is a classic Chinese patent medicine used in China for more than 1,000 years in treating gastrointestinal and respiratory diseases. Clinically applied HZOL in early respiratory disease stages can reduce the proportion of lung infection patients that progress to severe acute lung injury (ALI). However, few pharmacological studies evaluated its level of protection against ALI. We explored mechanisms of HZOL against ALI by employing network pharmacology, molecular docking, and rat experiments. Firstly, network pharmacology prediction and published biological evaluation of active ingredients of HZOL suggested that HZOL exerted the protective effect in treating ALI mainly in the areas of regulation of cell adhesion, immune response, and inflammatory response and closely related to the NF‐ κ B pathway. Secondly, molecular docking results demonstrated that imperatorin and isoimperatorin combined well with targets in the NF‐ κ B pathway. Finally, ALI rats induced by lipopolysaccharides (LPS) were used to validate prediction after pretreatment with HZOL for 2 weeks. Results confirmed that lung and colon injury occurred in ALI rats. Furthermore, HZOL exerts anti‐inflammatory effects on LPS‐induced ALI and gut injury by repairing lung and colon pathology, reducing and alleviating pulmonary edema, inhibiting abnormal enhancement of thymus and spleen index, modulating hematologic indices, and increasing levels of total short‐chain fatty acids (SCFAs) in the cecum. Additionally, abnormal accumulation of inflammatory cytokines IL‐6, IL‐1 β , TNF‐ α , and IFN‐ γ in serum and bronchoalveolar lavage fluid was significantly reduced after pretreating with HZOL. Furthermore, HZOL downregulated the expression of TLR4, CD14, and MyD88 and phosphorylation of NF‐ κ B p65 in lung tissue. Altogether, HZOL was found to exert an anti‐inflammatory effect regulation by increasing levels of SCFAs, inhibiting the accumulation of inflammatory cytokines, and attenuating the activation of the TLR4/NF‐ κ B p65 pathway. Our study provided experimental evidences for the application of HZOL in preventing and treating ALI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryNF-kappa BAnimalsRatsAnti-Inflammatory AgentsCytokinesLipopolysaccharidesLungMolecular Docking SimulationSignal TransductionToll-Like Receptor 4Fatty Acids, Volatile

Substanzen

Anti-Inflammatory AgentsCytokinesLipopolysaccharidesNF-kappa BTlr4 protein, ratToll-Like Receptor 4Fatty Acids, Volatile

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • School of Basic Medical Sciences, Anhui Medical University, Hefei, China.

ORCID-Profile: Ruying Tang, Jianjun Zhang, Rui Zhang, Linyuan Wang

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Tang, R., Zhang, J., Zhang, R., Li, X., Lv, R., Nan, H., Liu, J., Zhao, Z., He, W., & Wang, L. (2023). Huoxiang Zhengqi Oral Liquid Attenuates LPS‐Induced Acute Lung Injury by Modulating Short‐Chain Fatty Acid Levels and TLR4/NF‐ κ B p65 Pathway. BioMed Research International. https://doi.org/10.1155/2023/6183551

Vancouver

Tang R, Zhang J, Zhang R, Li X, Lv R, Nan H, et al. Huoxiang Zhengqi Oral Liquid Attenuates LPS‐Induced Acute Lung Injury by Modulating Short‐Chain Fatty Acid Levels and TLR4/NF‐ κ B p65 Pathway. BioMed Research International. 2023. doi:10.1155/2023/6183551

BibTeX
@article{Tang2023,
  author = {Tang, Ruying and Zhang, Jianjun and Zhang, Rui and Li, Xinyu and Lv, Ruilin and Nan, Haipeng and Liu, Jinlian and Zhao, Zhongpeng and He, Wei and Wang, Linyuan},
  title = {Huoxiang Zhengqi Oral Liquid Attenuates LPS‐Induced Acute Lung Injury by Modulating Short‐Chain Fatty Acid Levels and TLR4/NF‐ κ B p65 Pathway},
  journal = {BioMed Research International},
  year = {2023},
  doi = {10.1155/2023/6183551}
}
Kostenlos starten →